share_log

bluebird bio | 8-K: bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

SEC announcement ·  Mar 26 07:09
Summary by Moomoo AI
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will...Show More
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will restate its consolidated financial statements for 2022 and for the first three quarters of both 2022 and 2023 due to accounting errors related to lease agreements with contract manufacturers. The restatement is expected to result in an increase in lease assets and lease liabilities, as well as an increase in non-cash interest expense, but will not impact the company's cash position or revenue. The company plans to file its restated 2023 Form 10-K by April 16, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more